GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE1029.30-11.45 (-1.1 %)
PREV CLOSE ( ) 1040.75
OPEN PRICE ( ) 1035.65
BID PRICE (QTY) 1028.65 (16)
OFFER PRICE (QTY) 1029.90 (10)
VOLUME 23335
TODAY'S LOW / HIGH ( )1018.20 1043.15
52 WK LOW / HIGH ( )507.65 1068
NSE1029.45-9.9 (-0.95 %)
PREV CLOSE( ) 1039.35
OPEN PRICE ( ) 1039.35
BID PRICE (QTY) 1028.80 (1)
OFFER PRICE (QTY) 1029.30 (345)
VOLUME 336163
TODAY'S LOW / HIGH( ) 1017.50 1044.25
52 WK LOW / HIGH ( )507.4 1070
Peer Companies Price () Chg () Chg (%) EPS () TTM P/E Volume (000's) 1 Year Return (%)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.